On July 7, 2026, Health Canada granted approval for the use of Mounjaro tirzepatide in children aged 10 years and older who are living with type 2 diabetes. The decision authorizes the medication for this specific pediatric population across Canada. The approval covers the brand-name drug Mounjaro,…
Health Canada approved the medication Mounjaro, known generically as tirzepatide, on July 7, 2026. This approval is specifically for children who are 10 years old and older. These children must be living with type 2 diabetes. The regulatory decision applies to the entire country of Canada.
Mounjaro is the brand name for the active ingredient tirzepatide. The drug is now authorized for use in the pediatric population. The authorized indication is for the treatment of type 2 diabetes. Children aged 10 years and older are the target patients for this therapy. The medication is intended to help manage blood sugar levels in these patients.
The approval covers children from 10 years of age and older. These patients have a diagnosis of type 2 diabetes. Health Canada's decision makes Mounjaro available for this younger age group. The medication is intended for children who are currently living with type 2 diabetes. This age group is specifically defined as 10 years and older.
Health Canada's approval on July 7, 2026, allows Mounjaro tirzepatide to be used in children aged 10 and older with type 2 diabetes. This regulatory action provides a new treatment option for pediatric patients in Canada. The approval is limited to the indication of type 2 diabetes. The drug may be prescribed for children who meet the age and diagnosis criteria.
On July 7, 2026, Health Canada approved Mounjaro tirzepatide for use in children 10 years and older living with type 2 diabetes. The approval permits the medication to be used for this specific pediatric population across Canada. The drug is now available for children with type 2 diabetes who are at least 10 years old.
Peptides referenced: Tirzepatide.
Related reading: Americans Hit Record High in Use of GLP-1 Drugs, Medicare GLP-1 Bridge Raises Bone Loss Concerns for Older Adults, Secret Shopper Study Finds Easy Access to GLP-1 Weight-Loss Drugs Online, Kailera Obesity Pill Shows 9.8% Weight Loss in China Phase 3 Trial.